Literature DB >> 25742120

Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink.

Rosa Parisi1, Martin K Rutter2, Mark Lunt3, Helen S Young4, Deborah P M Symmons5, Christopher E M Griffiths4, Darren M Ashcroft6.   

Abstract

The association between psoriasis and risk of major cardiovascular (CV) events (myocardial infarction, acute coronary syndrome, unstable angina, and stroke) is unclear. A cohort study with 48,523 patients with psoriasis and 208,187 controls was conducted. During a median follow-up of 5.2 years, 1,257 patients with psoriasis (2.59%) had a major CV event, compared with 4,784 controls (2.30%). In the multivariable analysis, inflammatory arthritis hazard ratio (HR) 1.36 (1.18-1.58), diabetes HR 1.18 (1.06-1.31), chronic kidney disease HR 1.18 (1.07-1.31), hypertension HR 1.37 (1.29-1.45), transient ischemic attack HR 2.74 (2.41-3.12), atrial fibrillation HR 1.54 (1.36-1.73), valvular heart disease HR 1.23 (1.05-1.44), thromboembolism 1.32 (1.17-1.49), congestive heart failure HR 1.57 (1.39-1.78), depression HR 1.16 (1.01-1.34), current smoker HR 2.18 (2.03-2.33), age (year) HR 1.07 (1.07-1.07), and male gender HR 1.83 (1.69-1.98) were statistically significant for the risk of major CV events. The age- and gender-adjusted HRs of a major CV event for psoriasis were 1.10 (1.04-1.17) and for severe psoriasis 1.40 (1.07-1.84), whereas the fully adjusted HRs were attenuated to 1.02 (0.95-1.08) and 1.28 (0.96-1.69). In conclusion, neither psoriasis nor severe psoriasis were associated with the short-to-medium term (over 3-5 years) risk of major CV events after adjusting for known cardiovascular disease risk factors.

Entities:  

Mesh:

Year:  2015        PMID: 25742120     DOI: 10.1038/jid.2015.87

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  41 in total

1.  The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke; Anne-Marie Tobin; Brian Kirby
Journal:  Exp Dermatol       Date:  2011-04       Impact factor: 3.960

2.  Updating the Read Codes: user-interactive maintenance of a dynamic clinical vocabulary.

Authors:  D Robinson; E Schulz; P Brown; C Price
Journal:  J Am Med Inform Assoc       Date:  1997 Nov-Dec       Impact factor: 4.497

Review 3.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

Authors:  Deborah P M Symmons; Sherine E Gabriel
Journal:  Nat Rev Rheumatol       Date:  2011-05-31       Impact factor: 20.543

4.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors:  Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

5.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Authors:  O Ahlehoff; G H Gislason; M Charlot; C H Jørgensen; J Lindhardsen; J B Olesen; S Z Abildstrøm; L Skov; C Torp-Pedersen; P R Hansen
Journal:  J Intern Med       Date:  2010-11-29       Impact factor: 8.989

6.  Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan.

Authors:  Hui-Wen Lin; Kuo-Hsien Wang; Hsiu-Chen Lin; Herng-Ching Lin
Journal:  J Am Acad Dermatol       Date:  2011-01-08       Impact factor: 11.527

7.  Determinants of quality of life in patients with psoriasis: a study from the US population.

Authors:  Joel M Gelfand; Steven R Feldman; Robert S Stern; John Thomas; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

8.  Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk.

Authors:  Robert S Stern; Annemieke Huibregtse
Journal:  J Invest Dermatol       Date:  2011-01-20       Impact factor: 8.551

9.  Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis.

Authors:  Y B Brauchli; S S Jick; M Miret; C R Meier
Journal:  Br J Dermatol       Date:  2009-02-04       Impact factor: 9.302

Review 10.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-11-27       Impact factor: 7.580

View more
  37 in total

Review 1.  FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities.

Authors:  Jessica M Donigan
Journal:  J Clin Aesthet Dermatol       Date:  2015-07

Review 2.  Autoimmunity and autoimmune co-morbidities in psoriasis.

Authors:  Kazuhisa Furue; Takamichi Ito; Gaku Tsuji; Takafumi Kadono; Takeshi Nakahara; Masutaka Furue
Journal:  Immunology       Date:  2018-02-06       Impact factor: 7.397

Review 3.  Progress to Date in Advancing Stratified Medicine in Psoriasis.

Authors:  Claire Reid; Lis Cordingley; Richard B Warren; Christopher E M Griffiths
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

Review 4.  "Inflammatory skin march" in atopic dermatitis and psoriasis.

Authors:  Masutaka Furue; Takafumi Kadono
Journal:  Inflamm Res       Date:  2017-06-15       Impact factor: 4.575

5.  Feasibility of carotid artery PET/MRI in psoriasis patients.

Authors:  Prabhakar Rajiah; Mojgan Hojjati; Ziang Lu; Vijaya Kosaraju; Sasan Partovi; James K O'Donnell; Christopher Longenecker; Grace A McComsey; Jackelyn B Golden; Fuad Muakkassa; Scott Santilli; Thomas S McCormick; Kevin D Cooper; Neil J Korman
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-08-20

6.  The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events.

Authors:  Alexander Egeberg; Lone Skov; Aditya A Joshi; Lotus Mallbris; Gunnar H Gislason; Jashin J Wu; Justin Rodante; Joseph B Lerman; Mark A Ahlman; Joel M Gelfand; Nehal N Mehta
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

7.  Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.

Authors:  Joshua P Rivers; Tiffany M Powell-Wiley; Amit K Dey; Justin A Rodante; Jonathan H Chung; Aditya A Joshi; Balaji Natarajan; Aparna P Sajja; Abhishek Chaturvedi; Anshuma Rana; Charlotte L Harrington; Heather L Teague; Benjamin N Lockshin; Mark A Ahlman; Jianhua Yao; Martin P Playford; Joel M Gelfand; Nehal N Mehta
Journal:  JACC Cardiovasc Imaging       Date:  2017-10-18

Review 8.  Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms.

Authors:  Kaitlyn M Yim; April W Armstrong
Journal:  Rheumatol Int       Date:  2016-05-24       Impact factor: 2.631

Review 9.  Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Sukit Raksasuk
Journal:  Int Urol Nephrol       Date:  2018-04-11       Impact factor: 2.370

Review 10.  Psoriasis and comorbid diseases: Epidemiology.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.